Table 1.

Hormones before, during and after treatment.

	Baselinea	Post Opb	Cycle 7c	Cycle 8d	1 month post cycle 8e	2.5 month post cycle 8f	2 month post M-Rxg	4.5 month post M-Rxh	Reference range
Weeks since diagnosis	0	2	32	35	39	44	54	65
Thyroxine (µg/day)	0	0	0	25	32	37.5	37.5	25
Testosterone	6.7	<0.4	<0.4					<0.4	0.0–0.5 nmol/L
DHEA-S	17.7	0.2	<0.01					<0.01	0.01–0.7 µmol/L
Androstenedione	10.9	<1.0	<1.0					<1.0	<2 nmol/L
17-Hydroxyprogesterone	6.4	<1.0	<1.0					<1.0	<3.5 nmol/L
ACTH	3		133				<1	93	2–11 pmol/L
Cortisol	151	255					1630	24	170–500 nmol/L
Post-ACTH-cortisol	430	517							>400 nmol/L
Estradiol	<30		<30					<30	<80 pmol/L
LH (unstimulated)	<0.1		<0.1						0–2.5 IU/L
FSH (unstimulated)	0.3		0.3						0–6.5 IU/L
LH (stimulated)			2.3					9	0–2.5 IU/L
FSH (stimulated)			0.7					15	0–6.5 IU/L
Free T4			7.9	11	11.3	11	15	16	10–20 pmol/L
TSH			4	7.8	0.91	2.2	1.3	3.8	0.5–4.5 pmol/L

^aBaseline tests at the time of initial presentation showing elevated androgens and normal response to synthetic ACTH; ^bTests from after surgery showing normal androgen levels and normal response to synthetic ACTH; ^cTests following early breast development showing GnRH-independent precocious puberty and central hypothyroidism; ^d,e,g,fTests showing return to normal thyroid function with increasing doses of thyroxine; ^g,hCortisol and ACTH results following cessation of M-Rx and continuing supra-physiological hydrocortisone; ^hElevated gonadotrophins demonstrating central precocious puberty. Androgen and thyroid function results are normal.

M-Rx, mitotane treatment.